Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (Efavirenz)

Journal of Pharmaceutical Sciences

Volumn 96, Issue 11, 2007, Pages 2970-2977

  Gao, J Zh ^a   Hussain, M A ^a   Motheram, R ^b   Gray, D A B ^a   Benedek, I H ^c   Fiske, W D ^c   Doll, W J ^d   Sandefer, E ^d   Page, R C ^d   Digenis, G A ^e  

^a BRISTOL MYERS SQUIBB   (United States)

^b MEDICINES COMPANY   (United States)

^c Endo Pharmaceuticals   (United States)

^d Scintipharma Inc   (United States)

^e University of Kentucky   (United States)

Author keywords

Bioavailability; Gamma scintigraphy; Gastrointestinal transit; In vitro and in vivo disintegration and dissolution; Pharmacokinetics

Indexed keywords

EFAVIRENZ;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; STOMACH EMPTYING;

EID: 36849020049     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20962     Document Type: Article

References (13)

1. Physician's, Desk Reference. 2002-2006.
2. Fell JT, Digenis GA. 1984. Imaging and behaviour of solid oral dosage forms in vivo. Int J Pharm 22: 1-15.
3. Kaus LC, Fell JT, Sharma H, Taylor DC. 1984. On the intestinal transit of a single non-disintegrating object. Int J Pharm 20:315-323.
4. Digenis GA, Sandefer EP. 1991. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Thera Drug Carrier Syst 7:309-345.
5. Sun JX, Walter B, Sandefer EP, Page RC, Digenis GA, Ryo UY, Cipriano A, Maniara WM, Powell ML, Chan K. 1996. Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics. J Clin Pharmacol 36:230-237.
6. Kenyon CJ, Brown F, McClelland GR, Wilding IR. 1998. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (Saquinavir). Pharm Res 15:417-422.
7. Marathe PH, Sandefer EP, Kollia GE, Greene DS, Barbhaiya RH, Lipper RA, Page RC, Doll WJ, Ryo UY, Digenis GA. 1998. In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. J Pharmacokinet and Biopharm 26:1-20.
8. Hussain MA, Chang R-K, Sandefer EP, Page RC, Digenis GA. 2003. Evaluation of the in vivo disintegration of solid dosage forms of a bile acid sequestrant in dogs using gamma scintigraphy and correlation to in vitro disintegration. Pharm Res 20:460-464.
9. Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. 2002. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1 - infected men. J Infect Dis 186:1339-1343.
10. Gallia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15:698-705.
11. Horter D, Dressman JB. 1997. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 25: 3-14.
12. Bolhuis GK, Zuurman K, Wierik GHP. 1997. Improvement of dissolution of poorly soluble drugs by solid dispersion on a super disintegrant. II. The choice of super disintegrants and effect of granulation. Eur J Pharm Sci 5:63-69.
13. Katori N, Aoyagi N, Terao T. 1995. Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation. Pharm Res 12:237-243.